









































- effect in patients with type 2 diabetes. *Biomed Environ Sci* 27: 902-906.
169. Neerati P, Devde R, Gangi AK (2014) Evaluation of the effect of curcumin capsules on glyburide therapy in patients with type-2 diabetes mellitus. *Phytother Res* 28: 1796-1800.
170. Na LX, Li Y, Pan HZ, Zhou XL, Sun DJ, et al. (2013) Curcuminoids exert glucose-lowering effect in type 2 diabetes by decreasing serum free fatty acids: A double-blind, placebo-controlled trial. *Mol Nutr Food Res* 57: 1569-1577.
171. Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, et al. (2018) Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetologia* 61: 2461-2498.
172. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, et al. (2019) consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2019 executive summary. *Endocr Pract* 25: 69-100.
173. Turner MW (2003) the role of mannose-binding lectin in health and disease. *Mol Immunol* 40: 423-429.
174. Saraheimo M, Forsblom C, Hansen TK, Teppo AM, Fagerudd J, et al. (2005) Increased levels of mannan-binding lectin in type 1 diabetic patients with incipient and overt nephropathy. *Diabetologia* 48: 198-202.
175. Li XQ, Chang DY, Chen M, Zhao MH (2018) Complement activation in patients with diabetic nephropathy. *Diabetes Metab pii: S1262-3636(18)30078-8*.
176. Man X, Zhang H, Yu H, Ma L, Du J (2015) Increased serum mannose binding lectin levels are associated with diabetic retinopathy. *J Diabetes Complications* 29: 55-58.
177. Huang Q, Shang G, Deng H, Liu J, Mei Y et al. (2015) High mannose-binding lectin serum levels are associated with diabetic retinopathy in chinese patients with type 2 diabetes. *PLoS One* 10: e0130665.
178. Zhao SQ, Hu Z (2016) Mannose-binding lectin and diabetic nephropathy in type 1 diabetes. *J Clin Lab Anal* 30: 345-350.
179. Guan LZ, Tong Q, Xu J (2015) Elevated serum levels of mannose-binding lectin and diabetic nephropathy in type 2 diabetes. *PLoS One* 10: e0119699.
180. Hansen TK, Tarnow L, Thiel S, Steffensen R, Stehouwer CD, et al. (2004) Association between mannose-binding lectin and vascular complications in type 1 diabetes. *Diabetes* 53: 1570-1576.
181. Hovind P, Hansen TK, Tarnow L, Thiel S, Steffensen R, et al. (2005) Mannose-binding lectin as a predictor of micro albuminuria in type 1 diabetes: An inception cohort study. *Diabetes* 54: 1523-1527.
182. Pan L, Ye Y, Wo M, Bao D, Zhu F, et al. (2018) Clinical significance of hemostatic parameters in the prediction for type 2 diabetes mellitus and diabetic nephropathy. *Dis Markers* 2018: 5214376.
183. Pabalan N, Tiongco RE, Pandac JK, Paragas NA, Lasta SL, et al. (2018) Association and biomarker potential of elevated serum adiponectin with nephropathy among type 1 and type 2 diabetics: A meta-analysis. *PLoS One* 13: e0208905.
184. Ingelfinger JR, Rosen CJ (2019) clinical credence - sglt2 inhibitors, diabetes and chronic kidney disease. *N Engl J Med*.
185. American Diabetes Association (2016) Standards of medical care in diabetes. *Diabetes Care* 39: 1-109.
186. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, et al. (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. *N Engl J Med*.